Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Clin Drug Investig. 2019 May;39(5):441–451. doi: 10.1007/s40261-019-00764-x

Fig. 3.

Fig. 3

GMRs (90% CI) for suvorexant co-administered with the strong CYP3A inhibitor ketoconazole, the moderate CYP3A inhibitor diltiazem, or the strong CYP3A inducer rifampin, versus suvorexant alone, for suvorexant AUC0–∞ (top) and Cmax (bottom). AUC0– area under the concentration–time curve from time of administration to infinity, CI confidence interval, Cmax maximum observed concentration, CYP cytochrome P450, GMR least-squares geometric mean ratio